• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 11th October 2012

Meeting the Challenges of Drug Development in 2022: Summary of OHE’s 50th Anniversary Conference

To celebrate its 50th Anniversary, OHE held a conference this week, The Challenges and Economics of Drug Development in 2022, which explored the likely evolution of the key aspects of drug development over the next ten years. The conference was…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

To celebrate its 50th Anniversary, OHE held a conference this week, The Challenges and Economics of Drug Development in 2022, which explored the likely evolution of the key aspects of drug development over the next ten years. The conference was attended by over 100 participants from the public and private sectors; speakers and panellists included leaders from drug regulatory agencies, health technology assessment (HTA) groups, payers, the pharmaceutical industry, private foundations, and academia.

To celebrate its 50th Anniversary, OHE held a conference this week, The Challenges and Economics of Drug Development in 2022, which explored the likely evolution of the key aspects of drug development over the next ten years.  The conference was attended by over 100 participants from the public and private sectors; speakers and panellists included leaders from drug regulatory agencies, health technology assessment (HTA) groups, payers, the pharmaceutical industry, private foundations, and academia.

The conference identified two core themes that will define the challenges for drug development in the next ten years: new, evolving technologies and more difficult disease targets.

Dramatic advances in technology are having a critical impact on all aspects of drug development, from identification of areas for research through improving the value of a new product once on the market.  At every step in the process, the ability to collect and analyse data of increasing complexity and sophistication continues to grow and change.  The new technologies are producing results already; for example, clinical trials in some therapeutic areas are becoming more efficient through the use of diagnostic and monitoring tools that help select the most appropriate patients and better capture their responses to treatment.  The same approach is beginning to have practical application after approval as well, as personalised medicine (also called “stratified” or “precision” medicine) enhances the prospects for treating patients more effectively and safely.  At the same time, however, many diseases with great unmet medical need today are very difficult to understand and to treat; for example, cancers, autoimmune diseases and neurological diseases such as Alzheimer’s.

The speakers and panellists generally agreed that the most important advances in treatment over the next decade will be through the development and use of biopharmaceuticals, often with companion diagnostics and/or other monitoring technologies.  Indeed, biologics already account for about a third of the drugs now in R&D in the biopharmaceutical industry, with that share expected to grow.  Such drugs tend to be riskier to develop and more expensive to produce than “traditional” drugs. To encourage continued innovation and better spread risk, new ways of collaborating across stakeholders will be crucial.  This will include a broad range of interests:  those involved in R&D — companies, research centres and, in some cases, private foundations and other funders — as well as drug regulatory agencies, HTA bodies, payers and patient groups.

Specific observations and recommendations included the following.

  • Partnerships early in R&D can be vital in identifying which targets to select and how to demonstrate effectiveness most efficiently
  • New approaches to R&D that spread risks, and share benefits, are important to incentives for innovation and potentially involve a wide range of public and private parties
  • Encouraging innovation includes finding approaches to creating “clusters” of life sciences experts that can produce synergistic interactions, advancing science more quickly; the UK is exploring options for increasing acvtivity within and across its clusters
  • Decisions about clinical trials often can benefit from timely discussions involving companies, regulators, HTA agencies and patient groups that provide guidance – on end-points, for example – potentially enhancing efficiency and minimising cost
  • Efforts to harmonise the benefit-risk standards of different regulatory agencies should continue because these affect clinical trial design and, so, both development times and costs
  • Earlier licensing — or a different, “adaptive”,  approach to licensing — should be considered as a way to allow new products to reach the market sooner, with provisions for the collection of specific Phase IV data essential for fuller efficacy and safety profiles
  • Better, more open communication among all stakeholders is critical to ensuring that each is asking the right questions — based on a more accurate understanding of both challenges and capabilities than is prevalent today
  • New approaches to determining pricing and reimbursement should be developed that, for example, provide incentives for stratified medicine and for developing efficacy and safety data for more than one indication per product
  • Use of electronic health records, registries and other patient databases to link diagnosis, treatment and outcomes are key to improving knowledge of relative effectiveness and safety

The ultimate goal over the next decade, then, is to reduce uncertainty and cost in drug development to encourage innovation for the toughest diseases and at an affordable price.

Editor's note: The published proceedings may be downloaded by clicking here.

  • Drug Development/R&D
  • Economics of Innovation
  • 50th Anniversary

Related News

Prize event
  • News
  • January 2023

Professor Aidan Hollis wins first £40,000 OHE Policy Innovation Prize

Read more
MicrosoftTeams-image-6_0
  • News
  • June 2022

OHE’s 60th Anniversary Party – Celebrating Our Achievements and Looking Forward

Read more
  • News
  • October 2020

Opportunities to Increase Efficiency in Healthcare

Read more
  • News
  • September 2020

Cornerstones of ‘Fair’ Drug Coverage

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!